证券日报网讯花园生物9月5日在互动平台回答投资者提问时表示，公司"年产6000吨维生素A粉项目"已 按计划完成建设。"年产5000吨维生素B6项目"因进一步优化技术工艺和提升智能化水平，项目将延期 达到预定可使用状态，目前已处于试生产阶段。 （文章来源：证券日报） ...

Group 1 - The company announced the extension of the expected operational dates for several investment projects without changing the implementation subject, location, or investment scale [2] - The projects affected include the annual production of 6,000 tons of Vitamin A powder, 20,000 tons of Vitamin E powder, 5,000 tons of Vitamin B6, 200 tons of Biotin, and 10,000 tons of L-Alanine (fermentation method) along with a biomanufacturing pilot base project [2]

Group 1 - The company Zhejiang Huayuan Biopharmaceutical Co., Ltd. has issued convertible bonds to unspecified investors, with a total amount of RMB 1.2 billion [2][3] - The bonds have a maturity of 6 years, with an annual interest rate that increases from 0.3% in the first year to 2.5% in the sixth year [4][5] - The initial conversion price for the bonds is set at RMB 15.19 per share, subject to adjustments based on various corporate actions [5][6] Group 2 - The funds raised from the bond issuance will be used for projects including the production of 6,000 tons of Vitamin A powder and 20,000 tons of Vitamin E powder, with a total investment of RMB 134.446 million [12][13] - The company plans to adjust the use of raised funds, reallocating some towards a new project for producing 1 billion solid dosage forms and 8 million injections, with a total investment of RMB 19.11 million [22][23] - The project aims to enhance the company's R&D and production capabilities, addressing the growing demand for high-quality pharmaceuticals in various therapeutic areas [23][24] Group 3 - The company has faced increased competition in the generic drug market, prompting a strategic shift in its investment focus [21][24] - The new project is expected to improve the company's production efficiency and meet international quality standards, ultimately benefiting patients [23][25] - The project is aligned with national policies promoting the development of innovative pharmaceuticals and aims to strengthen the company's market position [26][27]